Procter & Gamble Health Share Price Today (PGHL)
TODAY IN ONE LINE
PGHL slipped 0.7% on light volume, in line with Nifty's -0.8% move, supported by recent strong earnings.
With a market cap of ₹11,174.62 Cr., it trades at a P/E of 34.28. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
Procter & Gamble Health flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Earnings GrowthEPS (TTM) grew by a solid 54.6% YoY
- ●Quarterly OutperformanceLatest quarter Sales up 19.1% and Profit up 54.6%
- ●High Capital EfficiencyROCE of 83.5% indicating pricing power
- ●Strong Return on EquityHealthy ROE of 61.6%
- ●Healthy Operating MarginsOPM is structurally strong at 32.4%
- ●High Promoter HoldingPromoters hold 51.8% skin-in-the-game
- ●Steady Dividend YieldReliable 2.34% dividend yield
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.00x
- ●Positive Free Cash FlowFCF has been positive for 3 consecutive years
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Rising Receivables vs SalesReceivables grew 53.1% outpacing sales growth of -18.9%
Latest Procter & Gamble Health News
What changed recently?
Recent events, corporate actions, and announcements.
Procter & Gamble Health Limited valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Procter & Gamble Health Limited, framed against the sector median so the premium or discount is obvious at a glance.
Procter & Gamble Health Limited trades at a P/E of 34.28× and P/B of 21.36×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
Procter & Gamble Health Limited technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Procter & Gamble Health Limited — derived from the live tape, not yesterday's close.
Procter & Gamble Health Limited last traded at ₹6,733 with an intraday range of ₹6,689.5–₹6,797 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹6733.00| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 7005.17 | +272.17 | +4.04% |
| R3 | 6897.67 | +164.67 | +2.45% |
| R2 | 6847.33 | +114.33 | +1.70% |
| R1 | 6790.17 | +57.17 | +0.85% |
| PIVOT | 6739.83 | 6.83 | 0.10% |
| CURRENT | 6733.00 | — | — |
| S1 | 6682.67 | -50.33 | -0.75% |
| S2 | 6632.33 | -100.67 | -1.50% |
| S3 | 6575.17 | -157.83 | -2.34% |
| S4 | 6467.67 | -265.33 | -3.94% |
PGHL is trading Below CPR, indicating Bearishness
CPR is Narrower, suggesting likely for trending moves
Day's range: ₹6720.5–₹6797
Trading Below opening range, showing Bearishness
Procter & Gamble Health Limited financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for Procter & Gamble Health Limited — consolidated or standalone — with margins, YoY growth and key ratios inline.
Procter & Gamble Health Limited reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹11,174.62 Cr. and reported EPS of ₹196.64.
Procter & Gamble Health segment analysis : revenue and profit mix.
Disclosed business segments at Procter & Gamble Health with their share of revenue and profit, switchable between consolidated and standalone reporting.
Procter & Gamble Health discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for Procter & Gamble Health Limited.
Our AI distills the core fundamental drivers supporting Procter & Gamble Health Limited, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
Procter & Gamble Health Limited's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Exceptional ROE 61.60% and ROCE 83.50% substantially exceed peer medians, signaling superior capital efficiency.
Operating margin 30.76% TTM significantly outpaces peer average ~18%, demonstrating pricing power and cost control.
Minimal debt-to-equity 0.0002x with net cash position ₹2,890.4 Cr reflects fortress-like balance sheet strength.
Promoter holding stable 51.82% demonstrates strong founder commitment and long-term value alignment.
Latest quarterly EPS grew 54.60% YoY, reflecting robust earnings momentum and operational excellence.
Key Risks.
P/E ratio 32.05x elevated relative to peer median 30.34x, suggesting premium valuation despite growth.
Price-to-book 20.92x significantly above peer median 3.42x indicates stretched valuation on book basis.
5-year revenue CAGR negative −7.18% despite TTM growth 19.10%, revealing structural decline offset by cyclical recovery.
Payout ratio 78.82% constrains reinvestment capacity and limits future growth capex flexibility.
52-week price return flat 0%, stock lacks recent momentum despite strong earnings acceleration.
Flip Conditions.
Valuation risk. a P/E above 45 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Return-quality risk. ROE below 57% would indicate weaker capital compounding.
Income thesis breaks if the dividend is cut or yield falls below 1.17%.
Procter & Gamble Health Limited peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Procter & Gamble Health Limited is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
Procter & Gamble Health Limited chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for Procter & Gamble Health Limited — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
- 1Pick how to scan. Detection sets sensitivity — Daily (standard) → Weekly (big swings). History sets how far back to look.
- 2Read the summary. The tiles at the top give the current read: net bias, the strongest pattern, and the one nearest to triggering.
- 3Scan the list. Use the Actionable, Watchlist, and History tabs to browse patterns. Click a pattern card to focus it.
- 4Inspect on the chart. Focusing draws the pattern’s pivots plus its break (blue), target (amber) and invalidation lines.
- 5Filter to what matters. Use the status controls (Confirmed, Forming, Invalidated) to hide noise and find exactly what you are looking for.
Pattern history — every completed pattern and its outcome
Procter & Gamble Health Limited delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Procter & Gamble Health Limited over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Procter & Gamble Health Limited stood at 55.4% of traded volume, against a 20-day average of 63.3%.
Procter & Gamble Health announcements: results, concalls, ratings, M&A.
Filings Procter & Gamble Health sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Procter & Gamble Health files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 73 documents below.
General Updates
Procter & Gamble Health Limited has informed the Exchange regarding revision in date of Company s Annual General Meeting for the Financial Year…
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Procter & Gamble Health Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
Trading Window
Procter & Gamble Health Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading)…
Investor Presentation
Procter & Gamble Health Limited has informed the Exchange about Investor Presentation
Analysts/Institutional Investor Meet/Con. Call Updates
Procter & Gamble Health Limited has informed the Exchange about Schedule of meet
Investor decks & rating reports.
Procter & Gamble Health dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Procter & Gamble Health has declared, sequenced by announce and record date.
Procter & Gamble Health corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Procter & Gamble Health Limited: business, sector, key facts.
What Procter & Gamble Health Limited does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Procter & Gamble Health Limited operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: PGHL, BSE: 500126.
Procter & Gamble Health Limited (PGHL) is a prominent player in the Indian pharmaceutical and consumer healthcare market, with an established international presence. Its core business revolves around the manufacturing and marketing of a diverse range of health-related products.
The company's product portfolio is primarily focused on over-the-counter (OTC) medications, vitamins, minerals, and dietary supplements. This caters to a broad consumer base seeking self-care solutions for various health needs. These products are marketed under several well-recognized brand names, including Polybion, Cosome, Evion, Neurobion, Nasivion, Livogen, and Seven Seas. Each brand likely targets specific segments within the healthcare market, offering specialized products to meet differing consumer demands.
PGHL's history traces back to 1967, originally operating under the name Merck Limited. The company underwent a significant rebranding in May 2019, adopting its current name to reflect its ownership under the Procter & Gamble umbrella. This change underscores the strategic alignment with the larger global Procter & Gamble corporation, leveraging its extensive resources and brand recognition for expansion and growth within the Indian and international markets.
The company's headquarters are located in Mumbai, India, strategically positioning it within a large and rapidly growing consumer market. Its status as a subsidiary of Procter & Gamble Overseas India BV further highlights its integration within the larger Procter & Gamble global network. This structure likely provides access to significant resources, technological advancements, and distribution channels, enhancing the company's competitiveness and market reach.
In summary, PGHL's business model centers on the development, production, and marketing of a diverse range of healthcare products targeting various consumer needs. Its strong brand portfolio, backed by the resources of Procter & Gamble, positions it for continued growth and success within the competitive healthcare landscape.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs and Pharmaceuticals (AKUMS) Share PricePeer
- Stocks near 52-week high (breakout watch)Screener
- Breakout Trader strategy playbookStrategy
- Top quality scorecard stocksScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about Procter & Gamble Health Limited (PGHL).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Procter & Gamble Health Limited (PGHL)?
The current share price of Procter & Gamble Health Limited (PGHL) is ₹6,733. Today, the stock has declined by ₹46.50 (0.69%), trading in a range of ₹6,689.5 to ₹6,797. The stock opened at ₹6,797 with a trading volume of 3,683 shares.
02Is Procter & Gamble Health Limited stock a good investment for long-term?
Procter & Gamble Health Limited can be considered for long-term investment based on several factors. The company has a market capitalization of ₹11,174.62 crores, P/E ratio of 34.28, ROE of 61.60%, and ROCE of 83.50%. The dividend yield stands at 2.34%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Procter & Gamble Health Limited stock?
The 52-week high price of Procter & Gamble Health Limited (PGHL) is ₹6,975, while the 52-week low is ₹4,707. Currently trading at ₹6,733, the stock is 89.3% away from its 52-week low and 3.5% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Procter & Gamble Health Limited stock at the current price?
Whether to buy Procter & Gamble Health Limited stock at ₹6,733 depends on multiple factors. The stock is currently trading with a P/E ratio of 34.28 and P/B ratio of 21.36. Today's performance shows a loss of 0.69%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Procter & Gamble Health Limited and when is the next dividend?
Procter & Gamble Health Limited offers a dividend yield of 2.34%, which means for every ₹100 invested at the current price of ₹6,733, you can expect to receive approximately ₹2.34 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Procter & Gamble Health Limited?
Procter & Gamble Health Limited's key financial metrics include: P/E Ratio: 34.28, P/B Ratio: 21.36, ROE: 61.60%, ROCE: 83.50%, Dividend Yield: 2.34%, EPS: ₹196.64, Book Value: ₹316.01, and Debt-to-Equity: 0.02. The company's market cap stands at ₹11,174.62 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Procter & Gamble Health Limited stock performing today in the market?
Procter & Gamble Health Limited stock opened at ₹6,797 and is currently trading at ₹6,733, showing a decline of ₹46.50 (0.69%). The intraday high is ₹6,797 and low is ₹6,689.5. The trading volume stands at 3,683 shares, indicating moderate market participation today.
08What is the P/E ratio of Procter & Gamble Health Limited and what does it indicate?
Procter & Gamble Health Limited has a Price-to-Earnings (P/E) ratio of 34.28, which means investors are willing to pay ₹34.28 for every ₹1 of earnings. With an EPS of ₹196.64, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Procter & Gamble Health Limited (PGHL) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.